Press Releases

JLP screening technology supports development of promising first-in-class anti-cancer therapeutics.

In a study recently published in the journal Nature, scientists from Acus Laboratories GmbH (Acus)  characterize a class of novel inhibitors of mitochondrial transcription (IMT).  

 

Altered expression of mitochondrial DNA and downstream activity of oxidative phosphorylation can be critical for cancer cell survival in numerous malignant tumors. In an interdisciplinary effort, small molecule inhibitors of mitochondrial transcription were developed, which induce a strong antitumor effect in in vivo cancer models. IMT thus not only provide a potent tool to study mitochondrial biology, but also harbor high therapeutic potential.

In this study, scientists from Acus validated the mitochondrial DNA polymerase as IMT drug target in live cells and mapped the drug-target binding interface by genetic screens. These pure genetic data were confirmed by a cryo-EM structure of the drug-protein complex. This work highlights the predictive power of the JLP screening technology to identify and validate drug target structures in an entirely unbiased manner. Importantly, this approach reaches amino acid resolution, thus resolving the drug-target binding site.

 

 

Rückfragen & Kontakt:


JLP Health GmbH
Himmelhofgasse 62
A-1130 Vienna
Tel.: 0043 664 6435991
Email: 
www.jlphealth.com

 

  

News

JLP screening technology supports development of promising first-in-class anti-cancer therapeutics.

In a study recently published in the journal Nature, scientists from Acus Laboratories GmbH (Acus)  characterize a class of novel inhibitors of mitochondrial transcription (IMT).  

 

Altered expression of mitochondrial DNA and downstream activity of oxidative phosphorylation can be critical for cancer cell survival in numerous malignant tumors. In an interdisciplinary effort, small molecule inhibitors of mitochondrial transcription were developed, which induce a strong antitumor effect in in vivo cancer models. IMT thus not only provide a potent tool to study mitochondrial biology, but also harbor high therapeutic potential.

In this study, scientists from Acus validated the mitochondrial DNA polymerase as IMT drug target in live cells and mapped the drug-target binding interface by genetic screens. These pure genetic data were confirmed by a cryo-EM structure of the drug-protein complex. This work highlights the predictive power of the JLP screening technology to identify and validate drug target structures in an entirely unbiased manner. Importantly, this approach reaches amino acid resolution, thus resolving the drug-target binding site.

 

 

Rückfragen & Kontakt:


JLP Health GmbH
Himmelhofgasse 62
A-1130 Vienna
Tel.: 0043 664 6435991
Email: 
www.jlphealth.com

 

  

News

JLP screening technology supports development of promising first-in-class anti-cancer therapeutics.

In a study recently published in the journal Nature, scientists from Acus Laboratories GmbH (Acus)  characterize a class of novel inhibitors of mitochondrial transcription (IMT).  

 

Altered expression of mitochondrial DNA and downstream activity of oxidative phosphorylation can be critical for cancer cell survival in numerous malignant tumors. In an interdisciplinary effort, small molecule inhibitors of mitochondrial transcription were developed, which induce a strong antitumor effect in in vivo cancer models. IMT thus not only provide a potent tool to study mitochondrial biology, but also harbor high therapeutic potential.

In this study, scientists from Acus validated the mitochondrial DNA polymerase as IMT drug target in live cells and mapped the drug-target binding interface by genetic screens. These pure genetic data were confirmed by a cryo-EM structure of the drug-protein complex. This work highlights the predictive power of the JLP screening technology to identify and validate drug target structures in an entirely unbiased manner. Importantly, this approach reaches amino acid resolution, thus resolving the drug-target binding site.

 

 

Rückfragen & Kontakt:


JLP Health GmbH
Himmelhofgasse 62
A-1130 Vienna
Tel.: 0043 664 6435991
Email: 
www.jlphealth.com

 

  

Press Releases

JLP screening technology supports development of promising first-in-class anti-cancer therapeutics.

In a study recently published in the journal Nature, scientists from Acus Laboratories GmbH (Acus)  characterize a class of novel inhibitors of mitochondrial transcription (IMT).  

 

Altered expression of mitochondrial DNA and downstream activity of oxidative phosphorylation can be critical for cancer cell survival in numerous malignant tumors. In an interdisciplinary effort, small molecule inhibitors of mitochondrial transcription were developed, which induce a strong antitumor effect in in vivo cancer models. IMT thus not only provide a potent tool to study mitochondrial biology, but also harbor high therapeutic potential.

In this study, scientists from Acus validated the mitochondrial DNA polymerase as IMT drug target in live cells and mapped the drug-target binding interface by genetic screens. These pure genetic data were confirmed by a cryo-EM structure of the drug-protein complex. This work highlights the predictive power of the JLP screening technology to identify and validate drug target structures in an entirely unbiased manner. Importantly, this approach reaches amino acid resolution, thus resolving the drug-target binding site.

 

 

Rückfragen & Kontakt:


JLP Health GmbH
Himmelhofgasse 62
A-1130 Vienna
Tel.: 0043 664 6435991
Email: 
www.jlphealth.com

 

  

Our disruptive Technology

We combine world leading advanced cell engineering with our unique technology to mine the function of the entire genome at an unprecedented single amino acid resolution

 

 

Operating Worldwide

Applying our unprecedented technology by a strong team of world leading scientific experts in Europe and China we are capable to deliver the next break-through drug.

image-115

ACUS LABORATORIES

We combine haploid cellular systems with unique state of the art genetic screening approaches to launch drug development projects based on novel target structures

ACUS - Our Company in Germany

The Acus Screening Technology has a clear advantage compared to approaches using RNAi or CRISPR/Cas9 technology, that fail to interrogate essential genes, and subsequently fail to identify the exact sites of drug action

image-116

JLP HEALTH - Our Experts and Advisors

A team of worldwide experts ignites the fire for groundbreaking discoveries

Our leading Experts

Scientific Advisory Board

Prof. Dr. Josef Penninger, MD
Dr. Norbert Bischofberger

 

Scientific Experts

Dr. Martin Denzel, PhD
 

image-117

Angal Biotechnology

Angalbio envisions to develop first-in-class treatment opportunities in China based on novel drug target structures emerging from mode of action studies of natural compounds

Our Joint Venture in China

Angalbio is established in Suzhou High Tech Zone as a Joint Venture of JLP Health GmbH with Jiangsu Provincial Industrial Technology Research Institute (JITRI) and Suzhou New High Tech District (SND) to create a leading player in the pharmaceutical market of mainland China